Current management of children and young people with heterozygous familial hypercholesterolaemia - HEART UK statement of care

Atherosclerosis. 2019 Nov:290:1-8. doi: 10.1016/j.atherosclerosis.2019.09.005. Epub 2019 Sep 12.

Abstract

This consensus statement on the management of children and young people with heterozygous familial hypercholesterolaemia (FH) addresses management of paediatric FH in the UK, identified by cascade testing when a parent is diagnosed with FH and for those diagnosed following incidental lipid tests. Lifestyle and dietary advice appropriate for children with FH; suggested low density lipoprotein cholesterol (LDL-C) targets and the most appropriate lipid-lowering therapies to achieve these are discussed in this statement of care. Based on the population prevalence of FH as ~1/250 and the UK paediatric population, there are approximately 50,000 FH children under 18 years. Currently only about 550 of these children and young people have been identified and are under paediatric care.

Keywords: Children and young people; Familial hypercholesterolaemia; Heterozygous familial hypercholesterolaemia; Lifestyle advice; Statin treatment.

Publication types

  • Practice Guideline
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adolescent
  • Age Factors
  • Child
  • Diet, Healthy*
  • Genetic Predisposition to Disease
  • Heterozygote*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Hyperlipoproteinemia Type II / blood
  • Hyperlipoproteinemia Type II / diagnosis
  • Hyperlipoproteinemia Type II / genetics
  • Hyperlipoproteinemia Type II / therapy*
  • Patient Transfer
  • Phenotype
  • Risk Factors
  • Risk Reduction Behavior*
  • Treatment Outcome
  • United Kingdom

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors